22
Participants
Start Date
August 5, 2016
Primary Completion Date
May 24, 2018
Study Completion Date
July 5, 2018
Mirbetriq (Mirabegron)
50mg of Mirabegron will be administered orally at time 0 in protocol A.
cold exposure
Acute cold exposure protocol using a water-conditioned cooling suit will be applied from time 120 to 300 min in protocol B
injection of 18FDG
I.v. injection of 18-fluorodeoxyglucose (18FDG) will be performed at time 270 min, followed by 30 min dynamic PET/CT scanning
injection of 11C-acetate
i.v. injection of 11C-acetate will be performed, followed by 20 min dynamic PET/CT scanning
[3-3H]-glucose
i.v. administration of 1.5 uCi/min of \[3-3H\]-glucose
[U-13C]-palmitate
i.v. administration of 0.08 umol/kg/min of \[U-13C\]-palmitate
2H-Glycerol
i.v. administration of 0.05 µmol/kg/min of 2H-glycerol
centre de recherche du CHUS, Sherbrooke
Université de Sherbrooke
OTHER